Scientific Health Development

SecondWave Systems develops an ultrasound stimulation platform that will give patients and their physicians a new option for treating debilitating or life-threatening diseases. Their technology utilizes non-invasive, low-intensity focused ultrasound to modulate nerves, cells, and organs deep within the body. They provide technology that suppresses neural and cellular pathways with the potential to treat many conditions, including inflammation, pain, and a variety of other disorders.

Liberate Medical, LLC is a medical device company focused on developing innovative solutions for patients with chronic obstructive pulmonary disease (COPD). Established in 2013 and headquartered in Crestwood, Kentucky, the company has created the VentFree system, which employs proprietary non-invasive neuromuscular electrical stimulation to contract abdominal wall muscles in synchrony with exhalation during mechanical ventilation. This technology aims to mitigate disuse atrophy of these muscles, potentially decreasing the duration of mechanical ventilation required for adult patients. By enhancing respiratory muscle function, Liberate Medical seeks to improve patient outcomes and reduce healthcare costs associated with the care of individuals with pulmonary disorders.

Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

Koya Medical, Inc. is a healthcare company based in Oakland, California, founded in 2018. The company specializes in developing innovative wearable therapeutic devices aimed at treating cancer-related chronic lymphedema and various venous diseases. Koya Medical's technology offers active compression therapy that enhances mobility and personalized care, addressing limitations commonly associated with traditional compression methods. Its sensor-based closed-loop system provides patient-specific patterned compression, enabling healthcare providers to effectively manage conditions like chronic edema and chronic venous insufficiency. Through its breakthrough treatments, Koya Medical seeks to transform the standard of care for individuals affected by these debilitating conditions.

Empirical Spine develops a stabilization system for orthopedics and spinal surgery, including LimiFlex, a paraspinous tension band that stabilizes the spine without compromising function for degenerative lumbar spinal disorders. Founded in 2015 and based in San Carlos, California, the company provides a minimally invasive flexion-restricting stabilization device designed to treat degenerative lumbar spinal disorders such as spinal stenosis with grade I degenerative spondylolisthesis, enabling secure spinal surgeries, supporting quicker recovery, and reducing long-term adjacent segment degeneration while preserving natural motion.

MiNDERA Corporation specializes in the development of non-invasive molecular testing devices aimed at diagnosing skin cancer and other skin diseases. The company has created a micro-needle array patch that allows for pain-free and minimally invasive extraction of biomarkers, such as RNA, DNA, and proteins, from the skin without the need for traditional biopsies. Additionally, MiNDERA develops specialized patches for whole transcriptome extraction and skin microbiome extraction, which are designed for research applications. Founded in 2013, MiNDERA is headquartered in Palo Alto, California.

Koya Medical, Inc. is a healthcare company based in Oakland, California, founded in 2018. The company specializes in developing innovative wearable therapeutic devices aimed at treating cancer-related chronic lymphedema and various venous diseases. Koya Medical's technology offers active compression therapy that enhances mobility and personalized care, addressing limitations commonly associated with traditional compression methods. Its sensor-based closed-loop system provides patient-specific patterned compression, enabling healthcare providers to effectively manage conditions like chronic edema and chronic venous insufficiency. Through its breakthrough treatments, Koya Medical seeks to transform the standard of care for individuals affected by these debilitating conditions.

Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

Procyrion, Inc. is a clinical-stage medical device company based in Houston, Texas, specializing in the design and manufacture of circulatory assist devices. The company has developed Aortix, a first-in-class heart pump that is deployed via catheter, providing a non-surgical solution for heart failure patients who do not respond to medication alone. Aortix is designed to alleviate symptoms of heart failure by disrupting the cardiorenal syndrome cycle, allowing the heart to rest and heal while improving blood flow to vital organs. This innovative device is notably compact, enabling cardiologists to implant it through a catheter in the leg, addressing critical needs in a population where only a small percentage of patients receive treatment due to the limitations of current solutions. Founded in 2005, Procyrion aims to enhance the quality of life for individuals suffering from heart failure, particularly those who are diuretic resistant.

Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

Procyrion, Inc. is a clinical-stage medical device company based in Houston, Texas, specializing in the design and manufacture of circulatory assist devices. The company has developed Aortix, a first-in-class heart pump that is deployed via catheter, providing a non-surgical solution for heart failure patients who do not respond to medication alone. Aortix is designed to alleviate symptoms of heart failure by disrupting the cardiorenal syndrome cycle, allowing the heart to rest and heal while improving blood flow to vital organs. This innovative device is notably compact, enabling cardiologists to implant it through a catheter in the leg, addressing critical needs in a population where only a small percentage of patients receive treatment due to the limitations of current solutions. Founded in 2005, Procyrion aims to enhance the quality of life for individuals suffering from heart failure, particularly those who are diuretic resistant.

Channel Medsystems, Inc. is a medical device company specializing in women’s healthcare technologies, particularly for endometrial ablation. Founded in 2009 and based in Emeryville, California, the company has developed an innovative cryothermic technology and a streamlined delivery system tailored for female patients and healthcare providers. Their devices integrate cryothermic energy into a self-contained, handheld unit, which eliminates the need for separate control units or additional capital equipment. Channel Medsystems aims to empower women to take control of their health journeys through its advanced cryotherapy solutions.

MiNDERA Corporation specializes in the development of non-invasive molecular testing devices aimed at diagnosing skin cancer and other skin diseases. The company has created a micro-needle array patch that allows for pain-free and minimally invasive extraction of biomarkers, such as RNA, DNA, and proteins, from the skin without the need for traditional biopsies. Additionally, MiNDERA develops specialized patches for whole transcriptome extraction and skin microbiome extraction, which are designed for research applications. Founded in 2013, MiNDERA is headquartered in Palo Alto, California.

Sight Sciences, Inc. is a medical device company specializing in the development and commercialization of technologies for the treatment of eye diseases, particularly glaucoma and dry eye conditions. Headquartered in Menlo Park, California, with an additional office in Southlake, Texas, the company offers the OMNI Surgical System, which allows surgeons to perform canaloplasty and trabeculotomy through a single device and corneal incision, thereby reducing intraocular pressure in patients with primary open-angle glaucoma. Additionally, Sight Sciences provides the TearCare System, a wearable eyelid technology that delivers targeted and adjustable thermal energy to the meibomian glands, addressing conditions like meibomian gland dysfunction and dry eye. Founded in 2010, the company aims to improve patient outcomes through innovative approaches in ophthalmic care.

MiNDERA Corporation specializes in the development of non-invasive molecular testing devices aimed at diagnosing skin cancer and other skin diseases. The company has created a micro-needle array patch that allows for pain-free and minimally invasive extraction of biomarkers, such as RNA, DNA, and proteins, from the skin without the need for traditional biopsies. Additionally, MiNDERA develops specialized patches for whole transcriptome extraction and skin microbiome extraction, which are designed for research applications. Founded in 2013, MiNDERA is headquartered in Palo Alto, California.

Procyrion, Inc. is a clinical-stage medical device company based in Houston, Texas, specializing in the design and manufacture of circulatory assist devices. The company has developed Aortix, a first-in-class heart pump that is deployed via catheter, providing a non-surgical solution for heart failure patients who do not respond to medication alone. Aortix is designed to alleviate symptoms of heart failure by disrupting the cardiorenal syndrome cycle, allowing the heart to rest and heal while improving blood flow to vital organs. This innovative device is notably compact, enabling cardiologists to implant it through a catheter in the leg, addressing critical needs in a population where only a small percentage of patients receive treatment due to the limitations of current solutions. Founded in 2005, Procyrion aims to enhance the quality of life for individuals suffering from heart failure, particularly those who are diuretic resistant.

MiNDERA Corporation specializes in the development of non-invasive molecular testing devices aimed at diagnosing skin cancer and other skin diseases. The company has created a micro-needle array patch that allows for pain-free and minimally invasive extraction of biomarkers, such as RNA, DNA, and proteins, from the skin without the need for traditional biopsies. Additionally, MiNDERA develops specialized patches for whole transcriptome extraction and skin microbiome extraction, which are designed for research applications. Founded in 2013, MiNDERA is headquartered in Palo Alto, California.

Channel Medsystems, Inc. is a medical device company specializing in women’s healthcare technologies, particularly for endometrial ablation. Founded in 2009 and based in Emeryville, California, the company has developed an innovative cryothermic technology and a streamlined delivery system tailored for female patients and healthcare providers. Their devices integrate cryothermic energy into a self-contained, handheld unit, which eliminates the need for separate control units or additional capital equipment. Channel Medsystems aims to empower women to take control of their health journeys through its advanced cryotherapy solutions.

AlgoMedica Inc., established in 2012 and headquartered in Palo Alto, California, specializes in developing software solutions for medical imaging. Its flagship product, PixelShine, is a server or cloud-based solution that enhances the quality of low-dose CT scan images, enabling radiologists to achieve standard protocol image quality using only 10% of the typical radiation dose. AlgoMedica's technology, based on artificial neural networks, is adaptable for various body parts and applications, including abdomen/pelvis, head, liver, and pediatric imaging.

Complexa, Inc. is a biopharmaceutical company focused on developing innovative medicines for severe and life-threatening conditions related to fibrosis and inflammation. Founded in 2008 and based in Berwyn, Pennsylvania, the company specializes in researching endogenous human cell signaling technologies to address a range of inflammatory, fibrotic, and central nervous system diseases. Its proprietary technology centers on the synthesis and therapeutic use of endogenous nitro-fatty acids, which serve as cell-signaling agents that modulate key inflammatory pathways. Notable among its developments is CXA-10, an oral nitrated fatty acid compound aimed at treating conditions such as focal segmental glomerulosclerosis and pulmonary arterial hypertension. Through its research efforts, Complexa aims to enhance existing anti-inflammatory and metabolic signaling mechanisms to support the resolution and repair of both acute and chronic tissue injuries.

EMKinetics, Inc. is a clinical-stage medical technology company based in San Francisco, California, that specializes in developing neuromodulation therapies using its proprietary Transdermal Stimulation (TranStim) technology. The company focuses on innovative treatments for conditions such as overactive bladder and other related ailments, employing electric pulses to prevent urinary incontinence. Founded in 2006, EMKinetics is dedicated to advancing its therapeutic offerings through cutting-edge research and development in the field of neuromodulation.

EMKinetics, Inc. is a clinical-stage medical technology company based in San Francisco, California, that specializes in developing neuromodulation therapies using its proprietary Transdermal Stimulation (TranStim) technology. The company focuses on innovative treatments for conditions such as overactive bladder and other related ailments, employing electric pulses to prevent urinary incontinence. Founded in 2006, EMKinetics is dedicated to advancing its therapeutic offerings through cutting-edge research and development in the field of neuromodulation.

CureDM, Inc. is a biopharmaceutical company based in Wilmington, Delaware, focused on developing and commercializing innovative therapies aimed at preventing, ameliorating, or reversing diabetes. Established in 2004, the company is dedicated to addressing both Type 1 and Type 2 diabetes through its lead product, Pancreate, a human peptide therapeutic. This drug candidate targets the regeneration of insulin-producing islets in the pancreas, with the potential to allow patients to discontinue insulin therapy.